Editor's Note: At OBR we have created an editorial board of renown thought leaders in different cancer disease areas. The role of our editorial board is to provide valuable insights through editorial commentary accompanying our daily news. We call it virtual access. By providing our insights into the daily news, you will have access into how these thought leading oncologists interpret the oncology news and events we carry in OBR daily. We hope that our editorial boards's insights will bring great value to the oncology community.
Professor and Chair, Department of Breast Medical Oncology The University of Texas MD Anderson Cancer Center
These findings are an example of the power of genomic sequencing and bioinformatic analysis - with a…
Associate Cancer Center Director, Yale Cancer Center Professor of Medicine, Yale School of Medicine New Haven, CT 06520
First approval for a biosimilar in solid tumor usage! This should help bring down the cost of bev b…
Director WVU Cancer Institute Director of Cancer Signature Program Laurence S. and Jean J. DeLynn Chair of Oncology
This is a very interesting study that opens the door to prospective investigation of a randomized tr…
Executive Director Community Oncology Alliance
This seems to be band-aiding the drug price issue, which near the root are the increasing discounts …
National Health Policy Expert
The developers of Value Metric Frameworks continue to struggle to make them relevant and also to mak…
Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Seattle, WA; CEO, Global Resource for Advancing Cancer Education (GRACE)
The results of the ALUR trial are impressive but not surprising at all. We should expect a second g…
President, W-Squared Group
The rationale is pretty simple. The branded drugs are now presenting deep rebate discounts, and brin…
Managing Director and Senior Biotechnology Analyst
I am excited to be joining the editorial board on OBR; I have been a fan of the publication since it…
Chief Medical Officer and Founder, N-of-One
No comments to show!
Professor and Director, Division of Hematology Oncology Department of Medicine,Cedars-Sinai Medical Center Associate Director for Academic Program Development Samuel Oschin Comprehensive Cancer Institute Professor of Medicine and Urology, Emeritus David Geffen School of Medicine at UCLA
This long awaited trial performed by the National Cancer Institute demonstrates the benefits of low …
FACP FACPE FASCO President, Minnesota Oncology
After a decade with only sorafenib for advanced HCC, it is refreshing to have several promising new …
CEO Tennessee Oncology
This is great news for community oncology. Barbara will be a great champion for us and the value we…
Vice President Integrated Community Oncology Network Former Community Representative ASCO Board of Directors
WOW...that is a hunk of change...BUT it would appear that Novartis is at least following some of the…
Florida Cancer Specialists President and Managing Partner
At Florida Cancer Specialists we have been using DigniCap for several months at 3 of our site and it…
Ronald H. Bloom Chair in Cancer Therapeutics
Professor and Chair, Department of Radiation Oncology
Interim Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
This article in the Washington Post highlights an area of interest as we enter an era of health care…
